Potentials for the use of glucocorticosteroids in inpatients with severe COVID-19
- Authors: Tsvetov V.M.1, Matveev A.V2, Mirzaev K.B2, Otdelnov V.A2, Sychev D.A2
-
Affiliations:
- Federal Center for Cardiovascular Surgery
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 28, No 10 (2021)
- Pages: 10-16
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313248
- DOI: https://doi.org/10.18565/pharmateca.2021.10.10-16
- ID: 313248
Cite item
Abstract
Full Text
About the authors
Vitaliy M. Tsvetov
Federal Center for Cardiovascular SurgeryCand. Sci. (Med.) Chelyabinsk, Russia
A. V Matveev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
K. B Mirzaev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
V. A Otdelnov
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
D. A Sychev
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
References
- WHO Collaborating Centre for Drug Statistics Methodology [Electronic resource]. 2021. URL: https://www.whocc.no/atc_ddd_index/7code=H02AB&showdescription=no (accessed: 09.07.2021)
- Государственный реестр лекарственных средств. Дексаметазон. Инструкция по медицинскому применению (Электронный ресурс)
- Государственный реестр лекарственных средств. Преднизолон. Инструкция по медицинскому применению (Электронный ресурс)
- Государственный реестр лекарственных средств. Метилпреднизолон. Инструкция по медицинскому применению (Электронный ресурс)
- Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin immunopathol. 2017;39(5):517-28. doi: 10.1007/s00281-017-0639-8.
- Schwiebert L.M., et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin immunol.
- Временные методические рекомендации Министерства здравоохранения РФ по профилактике, диагностике и лечению новой коронавирусной инфекции (COViD-19), версия 11 от 07.05.2021 (Электронный ресурс)
- RECOVERY Collaborative Group. N Engl J Med. 2021;384(8):693-704. Doi: 10.1056/ NEJMoa2021436.
- Salton F., Confalonieri P., et al. Prolonged Low-Dose Methylprednisolone in Patients With Severe COViD-19 Pneumonia / Open Forum infectious Diseases. 2020;7(issue 10):ofaa421. URL: 10.1093/ofid/ ofaa421.
- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COViD-19) Treatment Guidelines. National institutes of Health [Electronic resource]. URL: https://www.covid19treatmentguidelines.nih.gov
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically ill Patients With COViD-19. A Meta-analysis. JAMA. 2020;324(13):1330-41. Doi: 10.1001/ jama.2020.17023.
- Pasin L., Navalesi P., Zangrillo A., et al. Corticosteroids for Patients With Coronavirus Disease 2019 (COViD-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials/Journal of Cardiothoracic and Vascular Anesthesia. Published: 2021-02. Doi: 10.1053/j. jvca.2020.11.057.
- Brigham and Women's Hospital COVID-19 Protocols 2021 [Electronic resource]. URL: https://covidprotocols.org/(accessed: 09.07.2021).
- Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance 2020. [Electronic resource]. URL: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass- general-COViD-19-treatment-guidance.pdf Version 8.04/28/2021 (accessed: 09.07.2021).
- Corticosteroids for COVID-19. Living guidance. WHO ref. number WHO/2019-nCoV/ Corticosteroids/2020.1. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed: 12.07.2021)
- Coronavirus disease (COViD-19): Dexamethasone [Electronic resource]. URL: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid- 19-dexamethasone (accessed: 09.07.2021).
- Methylprednisolone for Patients With COViD-19 Severe Acute Respiratory Syndrome (MP-C19) [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/results/NCT04323592 (accessed: 09.07.2021).
- Ma S., Xu C., Liu S., et al. Efficacy and safety of systematic corticosteroids among severe COViD-19 patients: a systematic review and meta-analysis of randomized controlled trials. Sig Transduct Target Ther 6, 83 (2021). doi: 10.1038/s41392-021-00521-7.
- Budhathoki P., Shrestha D.B., Rawal E., Khadka S. Corticosteroids in COVID-19: is it Rational7 A Systematic Review and Meta-Analysis [published online ahead of print., 2020 Oct 19]. SN Compr Clin Med. 2020;1-21. doi: 10.1007/s42399-020-00515-6.
- van Paassen J., Vos J.S., Hoekstra E.M., et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24:696. Doi: 10.1186/ s13054-020-03400-9.
- Wu C., Chen X., Cai Y., et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published correction appears in JAMA Intern Med. 2020;180(7):1031]. JAMA Intern Med. 2020;180(7):934-43. doi: 10.1001/jamainternmed.2020.0994.
- Cano E.J., Fuentes X.F, Campioli C.C., et al. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. Chest. 2021;159(3):1019-40. Doi: 10.1016/j. chest.2020.10.054.
- Therapeutics and COVID-19: living guideline. WHO reference number: WHO/2019-nCoV/ therapeutics/2021.2. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2 (accessed: 13.07.2021).
- Cheng B., Ma J., Yang Y., et al. Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease. Front. Pharmacol. 2021;12:670170. Doi: 10.3389/ fphar.2021.670170.
- Rashad A, Mousa S., Nafady-Hego H., et al. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab. Sci Rep. 2021;11:8816. doi: 10.1038/s41598-021-88086-x.